Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Resistance Mechanism for Zanubrutinib in Marginal Zone Lymphoma.

Journal of the National Comprehensive Cancer Network : JNCCN - 23 Jun 2025

Sharp John, Shana'ah Arwa Y, Voorhees Timothy J, Bond David A, Sawalha Yazeed, Sigmund Audrey, Hanel Walter, Sehgal Lalit, Alinari Lapo, Baiocchi Robert, Maddocks Kami, Jones Dan, Christian Beth, Epperla Narendranath

Abstract excerpt

Marginal zone lymphoma (MZL) is the third most common B-cell non-Hodgkin lymphoma and tends to follow the relapsing course typical of other indolent lymphomas, meaning that many patients receive multiple lines of therapy. Brüton's tyrosine kinase inhibitors (BTKis) have been a promising addition to the treatment landscape of relapsed MZL; however, development of resistance to these agents remains a significant...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Agammaglobulinaemia Tyrosine Kinase
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lymphoma, B-Cell, Marginal Zone

Share to Phospholipase C gamma

Share to Piperidines

Share to Protein Kinase Inhibitors

Share to Pyrazoles

Share to Pyrimidines

Source

Identifiers

PMID: 40550489
DOI: 10.6004/jnccn.2025.7045

Genes

BTK
PLCG2

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Resistance Mechanism for Zanubrutinib in Marginal Zone Lymphoma.PMID 40550489Read ↗

Molecular associations of response to the new-generation BTK inhibitor zanubrutinib in marginal zone lymphoma.Semantic proximity Read ↗

High-Throughput Screening Identifies PLK1 Inhibition as a Strategy to Potentiate BTK Blockade in Marginal Zone LymphomaSemantic proximity Read ↗

Resistance to Bruton tyrosine kinase inhibitors: the Achilles heel of their success story in lymphoid malignancies.Semantic proximity Read ↗

A Review of Resistance Mechanisms to Bruton's Kinase Inhibitors in Chronic Lymphocytic Leukemia.Semantic proximity Read ↗

BTK Inhibitors and BTK Degraders for the Treatment of Mantle Cell Lymphoma - Current Status and PerspectivesSemantic proximity Read ↗

Genetic and Non-Genetic Mechanisms of Resistance to BCR Signaling Inhibitors in B Cell MalignanciesSemantic proximity Read ↗

Resistance mechanisms and approach to chronic lymphocytic leukemia after BTK inhibitor therapy.Semantic proximity Read ↗

Mechanisms of ibrutinib resistance in chronic lymphocytic leukaemia and non-Hodgkin lymphoma.Semantic proximity Read ↗

Optimizing therapy for nodal marginal zone lymphomaSemantic proximity Read ↗

SOHO State of the Art Updates and Next Questions: Updates on BTK Inhibitors for the Treatment of Chronic Lymphocytic Leukemia.Semantic proximity Read ↗

The genetic landscape of histologically transformed marginal zone lymphomasSemantic proximity Read ↗

Improved biological insight and influence on management in indolent lymphoma. Talk 3: update on nodal and splenic marginal zone lymphoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.